DHEC mesylate attenuates pathologies and aberrant bisecting N-glycosylation in Alzheimer's disease models

Neuropharmacology. 2024 Feb 6;248:109863. doi: 10.1016/j.neuropharm.2024.109863. Online ahead of print.ABSTRACTTremendous progress has been made to develop the therapy of Alzheimer's disease (AD). Existing several anti-AD remedies, with certain limitations, are far from adequate. Evidence suggests that dihydroergocristine (DHEC) mesylate, one of the main components of Ergoloid mesylates, can reduce the production of amyloid-β in vitro. However, the therapeutic effect of DHEC mesylate in AD and its underlying mechanism are still largely unknown. Herein, we characterized the pharmacological effect of DHEC mesylate in AD and found that the spatial memory disorders and Alzheimer-type pathologies were alleviated by DHEC mesylate administration. Moreover, we demonstrated that DHEC mesylate improved aberrant bisecting N-glycosylation, which was identified as a potential biomarker of AD. We further explored the underlying mechanism and confirmed that DHEC mesylate protected against AD via AMPK and ERK signaling, in which, AMPK was the dominant down-stream molecule of DHEC mesylate. In summary, our findings provide foundations for development of DHEC mesylate as a therapeutic approach for AD.PMID:38325771 | DOI:10.1016/j.neuropharm.2024.109863
Source: Neuropharmacology - Category: Drugs & Pharmacology Authors: Source Type: research